Cargando…
Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines
The epidermal growth factor (EGFR) receptor is frequently overexpressed in glioblastoma multiforme IV (GBM). Increased expression of EGFR leads to increased proliferation, decreased apoptosis, and increased resistance to chemotherapeutic agents. A small molecule called erlotinib inhibits EGFR recept...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527275/ https://www.ncbi.nlm.nih.gov/pubmed/36199696 http://dx.doi.org/10.3389/fphar.2022.952169 |
_version_ | 1784801048691474432 |
---|---|
author | Powe, Erika Parschauer, Daniel Istifan, Jessica Lin, Stacy Duan, Huanyun Gryka, Rebecca Jean-Louis, Denise Tiwari, Amit K. Amos, Samson |
author_facet | Powe, Erika Parschauer, Daniel Istifan, Jessica Lin, Stacy Duan, Huanyun Gryka, Rebecca Jean-Louis, Denise Tiwari, Amit K. Amos, Samson |
author_sort | Powe, Erika |
collection | PubMed |
description | The epidermal growth factor (EGFR) receptor is frequently overexpressed in glioblastoma multiforme IV (GBM). Increased expression of EGFR leads to increased proliferation, decreased apoptosis, and increased resistance to chemotherapeutic agents. A small molecule called erlotinib inhibits EGFR receptors by binding to their adenosine triphosphate (ATP) binding sites. It is FDA approved to treat a variety of EGFR-mediated cancers. Several clinical trials have explored a combination of erlotinib with other agents to treat glioblastoma since it is believed that erlotinib would benefit patients with GBM with EGFR mutations or expression. Luteolin, a natural flavonoid, inhibits cell growth and induces apoptosis in cancer cells. We investigated the combined effects of erlotinib and luteolin on proliferation and apoptosis on glioblastoma cell lines overexpressing EGFR or glioma cells expressing truncated EGFR (ΔEGFR). In a concentration-dependent fashion, the combination of luteolin and erlotinib reduced cell proliferation (p < 0.05) and induced apoptosis by cleaving PARP and increasing caspase expression. In addition, the combination of luteolin and erlotinib reduced the phosphorylation of downstream EGFR cell signaling molecules such as Akt, NF kappa B, and STAT3 in a concentration-dependent manner. These findings suggest that combining luteolin with erlotinib offers a potential treatment strategy for glioblastoma multiforme IV. |
format | Online Article Text |
id | pubmed-9527275 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95272752022-10-04 Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines Powe, Erika Parschauer, Daniel Istifan, Jessica Lin, Stacy Duan, Huanyun Gryka, Rebecca Jean-Louis, Denise Tiwari, Amit K. Amos, Samson Front Pharmacol Pharmacology The epidermal growth factor (EGFR) receptor is frequently overexpressed in glioblastoma multiforme IV (GBM). Increased expression of EGFR leads to increased proliferation, decreased apoptosis, and increased resistance to chemotherapeutic agents. A small molecule called erlotinib inhibits EGFR receptors by binding to their adenosine triphosphate (ATP) binding sites. It is FDA approved to treat a variety of EGFR-mediated cancers. Several clinical trials have explored a combination of erlotinib with other agents to treat glioblastoma since it is believed that erlotinib would benefit patients with GBM with EGFR mutations or expression. Luteolin, a natural flavonoid, inhibits cell growth and induces apoptosis in cancer cells. We investigated the combined effects of erlotinib and luteolin on proliferation and apoptosis on glioblastoma cell lines overexpressing EGFR or glioma cells expressing truncated EGFR (ΔEGFR). In a concentration-dependent fashion, the combination of luteolin and erlotinib reduced cell proliferation (p < 0.05) and induced apoptosis by cleaving PARP and increasing caspase expression. In addition, the combination of luteolin and erlotinib reduced the phosphorylation of downstream EGFR cell signaling molecules such as Akt, NF kappa B, and STAT3 in a concentration-dependent manner. These findings suggest that combining luteolin with erlotinib offers a potential treatment strategy for glioblastoma multiforme IV. Frontiers Media S.A. 2022-09-19 /pmc/articles/PMC9527275/ /pubmed/36199696 http://dx.doi.org/10.3389/fphar.2022.952169 Text en Copyright © 2022 Powe, Parschauer, Istifan, Lin, Duan, Gryka, Jean-Louis, Tiwari and Amos. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Powe, Erika Parschauer, Daniel Istifan, Jessica Lin, Stacy Duan, Huanyun Gryka, Rebecca Jean-Louis, Denise Tiwari, Amit K. Amos, Samson Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines |
title | Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines |
title_full | Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines |
title_fullStr | Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines |
title_full_unstemmed | Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines |
title_short | Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines |
title_sort | luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527275/ https://www.ncbi.nlm.nih.gov/pubmed/36199696 http://dx.doi.org/10.3389/fphar.2022.952169 |
work_keys_str_mv | AT poweerika luteolinenhanceserlotinibscellproliferationinhibitoryandapoptoticeffectsinglioblastomacelllines AT parschauerdaniel luteolinenhanceserlotinibscellproliferationinhibitoryandapoptoticeffectsinglioblastomacelllines AT istifanjessica luteolinenhanceserlotinibscellproliferationinhibitoryandapoptoticeffectsinglioblastomacelllines AT linstacy luteolinenhanceserlotinibscellproliferationinhibitoryandapoptoticeffectsinglioblastomacelllines AT duanhuanyun luteolinenhanceserlotinibscellproliferationinhibitoryandapoptoticeffectsinglioblastomacelllines AT grykarebecca luteolinenhanceserlotinibscellproliferationinhibitoryandapoptoticeffectsinglioblastomacelllines AT jeanlouisdenise luteolinenhanceserlotinibscellproliferationinhibitoryandapoptoticeffectsinglioblastomacelllines AT tiwariamitk luteolinenhanceserlotinibscellproliferationinhibitoryandapoptoticeffectsinglioblastomacelllines AT amossamson luteolinenhanceserlotinibscellproliferationinhibitoryandapoptoticeffectsinglioblastomacelllines |